Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Schizoaffective Disorder
  • Age: Between 18 - 65 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Diagnosis of schizophrenia or schizoaffective disorder
    2. Commission of a minor or serious act of violence against another person, or a threat with a weapon against another person, in the last six months
    3. Willing and able to provide informed consent
    4. Medically stable in judgment of physician providing study treatment
    5. Appropriate for treatment with either clozapine or treatment as usual (TAU)

You may not be eligible for this study if the following are true:

    1. An unstable or serious medical or neurological condition including a myeloproliferative disorder or condition that suppresses the bone marrow
    2. A history of intolerance/allergy to clozapine
    3. A history of intellectual impairment
    4. Pregnant or lactating women; women who are able to become pregnant but who are not willing to use effective methods of birth control
    5. Individuals who score a 3, 4, or 5 within the previous month on the suicidal ideation section of the Columbia-Suicide Severity Rating Scale, have any suicidal behavior (not including non-suicidal self-injury) within the previous 3 months, or are, in the opinion of the investigator, at too high of a risk for suicide to be safely treated in a randomized trial in which they may not be treated with clozapine
    6. Documented intolerance to or lack of any therapeutic benefit with clozapine after a full trial

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.